Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Aug 26, 2008 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that the Lead Investigator for its phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Perspectives in Melanoma XII meeting at The Hague, The Netherlands. Professor Thompson's presentation, entitled "PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma," is scheduled for the afternoon symposium on emerging therapies scheduled for approximately 2:20 pm local time on Thursday October 2nd, 2008.
"The presentation by Professor Thompson is expected to report data from the completed phase 1 clinical trial, as well as providing an update on the current phase 2 study," noted Craig Dees, PhD, CEO of Provectus.
Dees continued, "Professor Thompson is one of the world's foremost authorities on melanoma treatment and the global lead investigator for our PV-10 clinical trials. He recently made a presentation on July 25, 2008, at the inaugural Sydney Cancer Conference 2008, which can be accessed via our website (www.pvct.com). In addition, 'The 7:30 Report,' a highly acclaimed Australian Broadcasting Corporation current affairs program airing in Australia, ran a story entitled: 'Melanoma breakthrough: a simple and less invasive cure' on the treatment of melanoma with PV-10, which is also accessible on Provectus' website.
Dees continued, "We announced recently that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in the phase 2 study, with enrollment continuing at centers in Brisbane and Sydney, Australia, and at the M.D. Anderson Cancer Center in Houston, TX. We expect to announce additional sites in Australia and the U.S. in the coming months."
According to the American Cancer Society, in 2008 more than 62,000 people are expected to be diagnosed with melanoma in the in the US , the most serious form of skin cancer, leading to over 8,000 deaths this year.
About Perspectives in Melanoma XII
With a wealth of new data in this rapidly evolving field, Perspectives in Melanoma XII is designed to provide a comprehensive overview of recent advances and rigorous discussions of the most current and controversial topics in clinical research and contemporary therapy for melanoma. Led by authorities and current investigators in the field, the program will discuss several of the most promising and important on-going clinical trials. State-of-the-art presentations by experts in molecular biology, genetics, and immunology will provide a valuable educational experience for all melanoma-related disciplines.
For further details visit: http://www.imedex.com/appweb/announcements/a030-01.asp
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in development of oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP â?? Investor Relations
Bill Gordon, SVP â?? Media Relations
Posted: August 2008